Companies will collaborate on an AI-powered care improvement solution for patients with high-risk COPD
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, announced a multi-year partnership with Sanofi , an innovative global healthcare company, and Regeneron, a leading biotechnology company, to deploy and evaluate an AI-powered workflow solution for chronic obstructive pulmonary disease. With support from Sanofi and Regeneron, Viz.ai will investigate the use of the Viz COPD module, a care acceleration solution that will leverage electronic health record (EHR) data and artificial intelligence (AI) to advance the detection and management of high-risk COPD patients.
“At Sanofi, we’re excited to collaborate with Viz.ai to further address unmet needs in COPD care by leveraging AI,” said Paul Rowe, MD, ATSF & Head of Medical, Specialty Care at Sanofi. “With this collaboration, we will study the impact of the Viz COPD module, a streamlined AI-enabled EHR workflow to improve access to care and ultimately patient outcomes in COPD, a disease that remains underprioritized, underfunded and undertreated in comparison to other noncommunicable diseases.”
Health Technology Insights: IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials
COPD is a common, progressive lung disease that results in restricted airflow, making it difficult to breathe. There are an estimated 392 million people living with COPD globally, and it is the fourth leading cause of death worldwide. Furthermore, COPD adds significant strain to healthcare systems and with each case, healthcare utilization grows as symptoms progress, magnifying the economic toll of the disease. Many COPD patients fail to receive optimal treatment due to improper identification of risk level, poor care coordination, lack of monitoring and escalation, and high administrative barriers to therapy.3,4
The Viz COPD module will evaluate EHR data using natural language processing to screen and triage patients in line with established clinical guidelines, flagging high-risk individuals for further follow-up and care. The Viz COPD module builds upon Viz.ai’s presence in over 1,700 hospitals and health systems with over 60,000 healthcare providers on the platform to improve diagnosis and care across a range of disease areas, including the respiratory space. Together, Viz.ai, Sanofi, and Regeneron aim to maximize patient impact, particularly for patients who stand to benefit most from improved follow-up and care.
Health Technology Insights: CE Health Interactive Launches CME Grants to Address Migraine Disparities
“This collaboration with Sanofi and Regeneron is a major step forward in our mission to expand AI-driven care coordination across disease areas with critical unmet needs, such as COPD,” said Chris Mansi, MD, CEO and co-founder of Viz.ai. “Our approach aims to empower healthcare providers to deliver data-driven, guideline-directed care that meaningfully impacts patient outcomes. We look forward to collaborating with Sanofi and Regeneron to harness AI to accelerate advancements in disease management and improve patient access to care.”
Health Technology Insights: Pangea Laboratory Appoints John Moore as Chief Executive Officer
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
